A pelvic floor consists of ligaments and muscles running from the pubic bone to the coccyx, covering the walls of the pelvis. Just as with every group of muscles, exercise is possible to keep the muscles strong and healthy. Constricted movement, though-triggered by trauma or ailments such as arthritis-can stress the muscles to a point that will result in urinary incontinence.
Pelvic floor muscles have an important function of supporting the pelvic organs and controlling the function of the bladder, bowel, and uterus. Having strong pelvic floor muscles is necessary for bladder control, preventing prolapse of the organs, and preventing bowel or uterine disease.
Pelvic floor disorders (PFDs) are prevalent, occurring in about 40% of women and more than 10% of men. Pelvic floor diagnosis aids in determining any malfunction in the pelvic muscles that might lead to conditions like urinary incontinence, fecal incontinence, and other related disorders.
The rise in prevalence of neurodegenerative diseases has a notable indirect effect on the pelvic floor diagnostics market, with shared epidemiological and clinical characteristics, including the elderly population. Neurodegenerative diseases such as Parkinson's disease, Alzheimer's, and multiple sclerosis (MS) are typically associated with pelvic floor disorders (PFDs) due to neural deficits or impairments in muscle control.
For example, over 80% of individuals with MS experience some type of bladder dysfunction or impairment believed to necessitate diagnostic testing, such as urodynamic tests or imaging of the urinary tract. In addition, Parkinson’s disease causes a loss of coordination between the pelvic muscles leading to urinary incontinence or fecal incontinence.
The increased risk of developing PFD, and its overlaid risk with neurodegenerative diseases, creates coalescing demand for pelvic floor diagnostics among the elderly population who are at more risk for these conditions.
Enhancements in healthcare infrastructure and favorable reimbursement policies in developed countries such as North America and Europe, are also anticipated tp boostvthe market growth. These countries have strong healthcare systems that support earlier diagnosis, and multidisciplinary management of complex conditions.
Hospitals and specialized diagnostic centers are further taking a multidisciplinary approach by adding pelvic floor assessments to standard care for patients with neurodegenerative conditions. Clinical practice guidelines support the use of pelvic floor therapies to treat pelvic floor dysfunction, in order to decrease client complications such as urinary tract infections, skin breakdown, and social isolation due to incontinence.
There is an emerging market for pelvic floor diagnostics, driven by growing attention to women's health as a result of shifting societal views, advancements in medical understanding, and technological progress. Long overlooked, pelvic floor disorders (PFDs)-such as urinary incontinence, pelvic organ prolapse, and fecal incontinence-affect millions of women worldwide and are increasingly recognized as significant health concerns.
Key opinion leaders continue to emphasize the importance of addressing these conditions due to their profound impact on physical, emotional, and psychological well-being. As awareness grows, so does the demand for effective diagnostic tools and comprehensive care in this historically underserved area of women’s health.
Awareness is reshaping expectations and guiding the future of women’s healthcare by emphasizing early diagnosis and treatment-focused approaches. It aims to minimize risks through strategies such as preventive care and personalized treatment.
Pelvic floor disorders have been relatively underdiagnosed and undertreated in the past, although they're very common among women, especially across the trajectory of: giving birth, menopause or obesity. Historically, PFDs were stigmatized or dismissed as part of the deal with age or motherhood, and due to this, there has been less advocacy on behalf of women's health.
The aforementioned changes in advocacy have sought to tell the story that pelvic health is indeed a component of our health and part of being well. Recent public health campaigns and educational initiatives have been essential in providing pathways for women to navigate access to the care they need by highlighting the signs, symptoms and consequences of PFD while normalizing care-seeking behaviors.
The Urinary incontinence market segment is expected to experience significant growth with a higher CAGR during the forecast period, owing to the increasing prevalence of urinary incontinence, particularly among the aging population. Urinary incontinence (i.e., involuntary loss of urine) is a condition that impacts millions of people around the world and particularly women and older adults.
Urinary incontinence is increasingly becoming an important influence in the pelvic floor diagnostics industry, as healthcare systems across the globe are making changes to put a greater emphasis on managing this condition with early identification and innovative diagnostic technologies.
Urinary incontinence is one of the most prevalent pelvic floor disorders, whose frequency rate from patient referrals increases with age and personal lifetime experiences including childbirth and menopause. Research suggests that almost 25% to 45% of women will experience some degree of urinary incontinence during their lifetime, showing that urinary incontinence is a common issue with substantial social and economic costs.
Although the prevalence is lower in men than in women, it still warrants attention-particularly among older men or those with conditions such as prostate enlargement or complications from previous prostate surgery. The potential for urinary incontinence will continue to have an impact in future years with increased population aging or aging will result in further weakening to pelvic floor muscles for both sexes, increased dysfunctional bladder capacity and excessive urinary urgency.
The North American pelvic floor diagnostics market is growing significantly due to favorable reimbursement policies, heightened levels of awareness about pelvic floor disorders, and its advanced healthcare infrastructure.
The combination of demographic, technological, and economic factors means that North America, specifically the United States, has consistently captured a significant portion of the global market share. Over the years, North America's demographic, technological and economic factors have established it as a major contributor in pelvic floor diagnostics.
North America has a well-established health care system, encouraging widespread adoption of advanced diagnostic technologies used to diagnose pelvic floor disorders. As reported in 2024, the United States contributed to 81.5% of the North American pelvic floor diagnostics market value; indicating that there is a great deal or capacity for healthcare systems to implement state-of-the-art medical devices.
Indeed, diagnostic technologies such as urodynamic testing systems, high-resolution ultrasound imaging, and dynamic MRI are widely accessible hospitals and diagnostic specialty treatment settings throughout the region. Highly trained staff members and effective diagnostic technology (and strategies) help ensure accurate diagnosis and management of pelvic floor disorders in those settings.
NA
NA
NA
Copyright © Transparency Market Research, Inc. All Rights reserved
Trust Online
Pelvic Floor Diagnostics Market
